Full text is available at the source.
Abstract
The efficacy and safety of tirzepatide compared to semaglutide is evaluated in individuals with a BMI of 25 kg/m² or higher.
- Tirzepatide and semaglutide are both considered for treating obesity under Japan's national insurance criteria.
- Obesity is defined by a body mass index (BMI) of 25 kg/m² or more with excess fat.
- The evaluation focuses on pharmacotherapy options for eligible individuals.
Simplified